Logista Pharma
Logista Pharma is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible for cisplatin-based chemotherapy.
Sponsor Fundacion Para El Progreso De La Oncologia En Cantabria
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase IIIB study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Newly Diagnosed pMMR Advanced or Recurrent Endometrial Cancer in Spain. DUoENDE Study
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Sponsor Fundacion De investigacion De Hm Hospitales
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase IIIb study of durvalumab as consolidation treatment for patients diagnosed with limited stage small cell lung cancer who have not progressed following definitive concurrent or sequential platinum-based chemoradiation therapy in Spain (ALBORAN).
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF V600E mutated MSS initially resectable or potentially resectable advanced colorectal cancer.
Sponsor Asociacion Grupo Tratamiento De Tumores Digestivos
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase IIIB study to evaluate the use of capivasertib in combination with fulvestrant in patients with HR+ / HER2- advanced breast cancer who have relapsed/progressed on ET and CDK4/6 inhibitor reflecting Real World Clinical Practice in Spain: CAPItana Study.
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
The SOUND-MCL study: A single-arm, open-label, multicenter, phase II study of acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain
Sponsor Astrazeneca Farmaceutica Spain S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations
Sponsor Asociacion Grupo Tratamiento De Tumores Digestivos
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)
Sponsor Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS
Sponsor Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multicenter, double-blind, randomized, placebo-controlled, dose-response trial with the full-spectrum Cannabis Extract VER-01 in patients with chronic non-specific low back pain
Sponsor Vertanical GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Logista Pharma?
The 2026-10-09 snapshot links Logista Pharma to 11 distinct CTIS trials. Recorded services include Manufacturing and Import, Medicinal product management, IMP Delivery, Logistics and procurement of rescue medicines. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Logista Pharma?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Logista Pharma conducted?
The linked trials record locations in 5 countries, including Spain, Germany, Czechia, Italy, Poland. These are trial locations, not confirmed office locations or countries where Logista Pharma delivered services.
What can this page tell me about Logista Pharma's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Logista Pharma. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Logista Pharma S.A.